Antibacterials branch

* 15% royalty income increase * 11% total revenue increase * Tripled net cash position * Phase 3 program with fosmanogepix progressing as planned * Financial guidance FY 2026: Double-digit increase in total revenue and operating profit * Conference call and webcast today at 4 p.m. (CET) Ad hoc announcement pursuant to Art.

* Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam * Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as planned * Two new preclinical collaborations to develop novel antibacterial and antifungal drugs * Cresemba continued strong double-digit in-market sales growth Allschwil, Switzerland, January 08, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage...

* Cresemba(®) and Zevtera(®)-related revenues rise by 24% to CHF 90.5 million * Total revenue grows significantly by 36% to CHF 104.0 million * Operating profit surges by 160% to CHF 24.0 million * Operating cash flow increases by 29% to CHF 23.1 million * Full-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic Ad hoc announcement pursuant to Art.